Skip to Content
MilliporeSigma
All Photos(1)

Documents

880620P

Avanti

18:0 PEG750 PE

Avanti Research - A Croda Brand 880620P, powder

Synonym(s):

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] (ammonium salt)

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 200 mg (880620P-200mg)
pkg of 1 × 25 mg (880620P-25mg)

manufacturer/tradename

Avanti Research - A Croda Brand 880620P

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@@](COP([O-])(OCCNC(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O.[NH4+]

General description

18:0 PEG750 PE is a polyethylene glycol (PEG) conjugated phospholipid. The molecular weight and exact mass are averages based on the polydispersity of PEG.

Application

18:0 PEG750 PE might be used to PEGylate lipoplexes and to study the feasibility of its entrapment into a solid matrix system for prolonged delivery of siRNA in vaginal mucus.

Biochem/physiol Actions

18:0 PEG750 PE is useful as a micelle-forming component.

Packaging

20 mL Clear Glass Screw Cap Vial (880620P-200mg)
5 mL Clear Glass Sealed Ampule (880620P-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rupa R Sawant et al.
International journal of pharmaceutics, 374(1-2), 114-118 (2009-05-19)
Cell-penetrating peptide (TATp) was attached to the distal tips of polyethyleneglycol (PEG) moieties of polyethyleneglycol-phosphatidylethanolamine (PEG-PE) micelles loaded with paclitaxel (PCT). The TATp-modified micelles demonstrated an increased interaction with cancer cells compared to non-modified micelles resulting in a significant increase
Tania Furst et al.
Journal of controlled release : official journal of the Controlled Release Society, 236, 68-78 (2016-06-23)
Topical vaginal sustained delivery of siRNA presents a significant challenge due to the short residence time of formulations. Therefore, a drug delivery system capable to adhere to the vaginal mucosa is desirable, as it could allow a prolonged delivery and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service